These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26403284)

  • 1. Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.
    Ferraz-Amaro I; Seoane-Mato D; Sánchez-Alonso F; Martín-Martínez MA;
    Rheumatol Int; 2015 Nov; 35(11):1825-36. PubMed ID: 26403284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability in the prescription of biological drugs in rheumatoid arthritis in Spain: a multilevel analysis.
    López-Longo FJ; Seoane-Mato D; Martín-Martínez MA; Sánchez-Alonso F;
    Rheumatol Int; 2018 Apr; 38(4):589-598. PubMed ID: 29368023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
    Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
    Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
    Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
    Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice.
    Naranjo A; Cáceres L; Hernández-Beriaín JÁ; Francisco F; Ojeda S; Talaverano S; Nóvoa-Medina J; Martín JA; Delgado E; Trujillo E; Álvarez F; Magdalena L; Rodríguez-Lozano C
    Rheumatol Int; 2015 Nov; 35(11):1851-5. PubMed ID: 26238094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
    Hetland ML; Jensen DV; Krogh NS
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain.
    Silva-Fernández L; Pérez-Vicente S; Martín-Martínez MA; López-González R;
    Semin Arthritis Rheum; 2015 Jun; 44(6):633-40. PubMed ID: 25563529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study.
    Michaud K; Pedro S; Wipfler K; Agarwal E; Katz P
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1322-1331. PubMed ID: 33787086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.
    Emery P; Solem C; Majer I; Cappelleri JC; Tarallo M
    Rheumatol Int; 2015 Nov; 35(11):1837-49. PubMed ID: 26164150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
    Hernández-Muñoz JJ; Wei W; Sierra-Zorita R
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):199-206. PubMed ID: 32475025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncompliance with guidelines on proton pump inhibitor prescription as gastroprotection in hospitalized surgical patients who are prescribed NSAIDs.
    van den Bemt PM; Chaaouit N; van Lieshout EM; Verhofstad MH
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):857-62. PubMed ID: 27046006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.
    Nikiphorou E; Galloway J; van Riel P; Yazici Y; Haugeberg G; Ostor A; Gogus F; Kauppi M; Sokka T;
    Clin Exp Rheumatol; 2017; 35(3):477-483. PubMed ID: 28134086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study.
    Radner H; Yoshida K; Hmamouchi I; Dougados M; Smolen JS; Solomon DH
    J Rheumatol; 2015 Jul; 42(7):1099-104. PubMed ID: 26034147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
    Crane MM; Juneja M; Allen J; Kurrasch RH; Chu ME; Quattrocchi E; Manson SC; Chang DJ
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1646-55. PubMed ID: 26097059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug prescribing trends in adults with rheumatoid arthritis: a population-based comparative study from 2005 to 2014.
    Zamora-Legoff JA; Myasoedova E; Matteson EL; Achenbach SJ; Crowson CS
    Clin Rheumatol; 2016 Oct; 35(10):2427-36. PubMed ID: 27334113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.